XML 56 R44.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaborative Arrangements and Licensing Agreements, Novartis (Details) $ in Thousands, shares in Millions | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | ---
Jul. 31, 2017 USD ($) | Jan. 31, 2017 Drug | Sep. 30, 2018 USD ($) | Sep. 30, 2017 USD ($) | Mar. 31, 2017 USD ($) PerformanceObligation shares | Sep. 30, 2018 USD ($) | Sep. 30, 2017 USD ($) | Dec. 31, 2017 USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Proceeds from sale of common stock to Novartis in a private placement |  |  |  |  |  | $ 0 | $ 50,000 |
Revenue |  |  | $ 145,395 | $ 118,314 |  | 407,559 | 346,387 |
Deferred revenue |  |  |  |  |  |  |  | $ 233,362
R&D [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Revenue |  |  | 62,639 | $ 83,697 |  | 225,584 | $ 280,281 |
Novartis [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Shares issued (in shares) | shares |  |  |  |  | 1.6 |  |  |
Proceeds from sale of common stock |  |  |  |  | $ 100,000 |  |  |
Number of separate performance obligations | PerformanceObligation |  |  |  |  | 4 |  |  |
Transaction price |  |  |  |  | $ 108,400 |  |  |
Premium received on shares issued |  |  |  |  | 28,400 |  |  |
Potential premium received if common stock is purchased in the future |  |  |  |  | 5,000 |  |  |
Deferred revenue |  |  | $ 34,800 |  |  | $ 34,800 |  | $ 70,700
Novartis [Member] | Revenue [Member] | Strategic Partner [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Concentration percentage |  |  | 5.00% | 8.00% |  | 10.00% | 6.00% |
Novartis [Member] | Minimum [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Number of drugs with exclusive option that could be exercised | Drug |  | 1 |  |  |  |  |  |
Novartis [Member] | R&D Services for AKCEA-APO(a)-L [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Transaction price |  |  |  |  | 64,000 |  |  |
Novartis [Member] | Delivery of AKCEA-APO(a)-L [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Transaction price |  |  |  |  | 1,500 |  |  |
Novartis [Member] | R&D Services for AKCEA-APOCIII-L [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Transaction price |  |  |  |  | 40,100 |  |  |
Novartis [Member] | Delivery of AKCEA-APOCIII-L [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Transaction price |  |  |  |  | 2,800 |  |  |
Novartis [Member] | R&D [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Revenue |  |  | $ 7,200 | $ 9,900 |  | $ 42,700 | $ 21,700 |
Akcea [Member] | Novartis [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  | 75,000 |  |  |
Portion of upfront payment retained |  |  |  |  | 60,000 |  |  |
Portion of upfront payment paid as a sublicense fee |  |  |  |  | $ 15,000 |  |  |
License fee receivable per drug |  |  | 150,000 |  |  | $ 150,000 |  |
Percentage of license fees, milestone payments and royalties paid as sublicense fee |  |  |  |  |  | 50.00% |  |
Proceeds from sale of common stock to Novartis in a private placement | $ 50,000 |  |  |  |  |  |  |
Akcea [Member] | Novartis [Member] | AKCEA-APO(a)-L [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Maximum amount of payments receivable for milestones |  |  | 600,000 |  |  | $ 600,000 |  |
Maximum amount of payments receivable for development milestones |  |  | 25,000 |  |  | 25,000 |  |
Maximum amount of payments receivable for regulatory milestones |  |  | 290,000 |  |  | 290,000 |  |
Maximum amount of payments receivable for commercialization milestones |  |  | 285,000 |  |  | $ 285,000 |  |
Royalty percentage received on sales of drug |  |  |  |  |  | 20.00% |  |
Akcea [Member] | Novartis [Member] | AKCEA-APOCIII-L [Member] |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |
Maximum amount of payments receivable for milestones |  |  | 530,000 |  |  | $ 530,000 |  |
Maximum amount of payments receivable for development milestones |  |  | 25,000 |  |  | 25,000 |  |
Maximum amount of payments receivable for regulatory milestones |  |  | 240,000 |  |  | 240,000 |  |
Maximum amount of payments receivable for commercialization milestones |  |  | $ 265,000 |  |  | $ 265,000 |  |
Royalty percentage received on sales of drug |  |  |  |  |  | 20.00% |  |

X
- References No definition available. + Details
Name: | ions_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix: | ions_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The license fee payment receivable per drug under the collaboration agreement. + References No definition available. + Details
Name: | ions_LicenseFeePaidPerDrug
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments receivable for commercialization milestones under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments receivable for development milestones under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments receivable for milestones under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableForMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments receivable for regulatory milestones under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The number of drugs with an exclusive option that could be exercised to develop and commercialize the drug and a license fee is paid under the collaboration agreement. The collaboration partner will assume all further global development, regulatory and commercialization activities for the licensed drug. + References No definition available. + Details
Name: | ions_NumberOfDrugsWithExclusiveOptionThatCouldBeExercised
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of license fees, milestone payments and royalties paid as sublicense fee under the collaboration agreement. + References No definition available. + Details
Name: | ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee
Namespace Prefix: | ions_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of the upfront payment received during the period under the collaboration agreement that was paid as a sublicense fee. + References No definition available. + Details
Name: | ions_PortionOfUpfrontPaymentPaidAsASublicenseFee
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of the upfront payment received during the period under the collaboration agreement that was retained by the entity. + References No definition available. + Details
Name: | ions_PortionOfUpfrontPaymentRetained
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The potential premium received if common stock is purchased in the future under a Stock Purchase Agreement (SPA) in conjunction with the collaboration agreement. + References No definition available. + Details
Name: | ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInTheFuture
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The total amount of the premium received over the trading price of common stock at the time of purchase. + References No definition available. + Details
Name: | ions_PremiumReceivedOnSharesIssued
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from the sale of common stock, including the premium paid for the purchase of common stock. + References No definition available. + Details
Name: | ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of separate performance obligations under the collaboration agreement. + References No definition available. + Details
Name: | ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of consideration the Company is eligible to earn under the collaboration agreement, including any variable consideration. + References No definition available. + Details
Name: | ions_RevenueFromContractWithCustomerTransactionPrice
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Royalty percentage received on the sales of a drug by a collaboration partner under the collaboration agreement. + References No definition available. + Details
Name: | ions_RoyaltyPercentageReceivedOnSalesOfDrug
Namespace Prefix: | ions_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of upfront payments received during the period under the collaboration agreement. + References No definition available. + Details
Name: | ions_UpfrontPaymentReceived
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOfPrivatePlacement
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_DeliveryOfAKCEAAPOALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_DeliveryOfAKCEAAPOCIIILMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_AKCEAAPOALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_AKCEAAPOCIIILMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |